Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Raised to $20.00 at Wells Fargo & Company

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price objective upped by Wells Fargo & Company from $19.00 to $20.00 in a research note published on Friday,Benzinga reports. They currently have an equal weight rating on the stock.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Friday, May 8th. Bank of America reaffirmed an “underperform” rating and issued a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Barclays lowered their price objective on shares of Amphastar Pharmaceuticals from $23.00 to $20.00 and set an “equal weight” rating for the company in a research note on Wednesday, June 3rd. Jefferies Financial Group reaffirmed a “hold” rating and issued a $22.00 price target (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. Finally, Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 11th. Six investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $22.00.

Amphastar Pharmaceuticals Trading Up 4.9%

Shares of AMPH opened at $20.78 on Friday. The business’s 50-day moving average price is $19.66 and its 200-day moving average price is $21.39. The company has a quick ratio of 2.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.79. The stock has a market cap of $916.19 million, a PE ratio of 12.30, a P/E/G ratio of 4.18 and a beta of 0.89. Amphastar Pharmaceuticals has a twelve month low of $16.65 and a twelve month high of $31.26.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.92%. The business had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. On average, equities analysts forecast that Amphastar Pharmaceuticals will post 2.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently bought and sold shares of the business. Quarry LP bought a new position in Amphastar Pharmaceuticals during the third quarter valued at approximately $32,000. Farther Finance Advisors LLC lifted its stake in shares of Amphastar Pharmaceuticals by 46.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after buying an additional 437 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Amphastar Pharmaceuticals by 24.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,233 shares of the company’s stock worth $60,000 after acquiring an additional 435 shares during the period. TD Private Client Wealth LLC grew its holdings in Amphastar Pharmaceuticals by 410.1% during the 4th quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock valued at $65,000 after buying an additional 1,944 shares in the last quarter. Finally, Quadrant Capital Group LLC purchased a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at about $82,000. 65.09% of the stock is currently owned by institutional investors.

More Amphastar Pharmaceuticals News

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Amphastar reported second-quarter revenue of $183.9 million, exceeding analysts’ approximately $179.9 million estimate. Adjusted earnings were $0.91 per share, well above consensus estimates ranging from $0.62 to $0.66 and up from $0.85 a year earlier. GAAP net income totaled $30.3 million, or $0.67 per share, while adjusted net income was $40.8 million. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
• Positive Sentiment: The earnings beat was broad enough to attract attention from analysts, with coverage highlighting stronger-than-expected revenue, EPS and other key quarterly metrics. The results provide a positive near-term catalyst for AMPH and help support its valuation despite the stock remaining below its 200-day moving average. Amphastar Pharmaceuticals Q2 Earnings and Revenues Top Estimates
• Neutral Sentiment: Wells Fargo raised its price target from $19 to $20 but maintained an “equal weight” rating. The revised target remains below the recent trading level, signaling limited perceived upside despite the earnings performance. Wells Fargo price-target update
• Negative Sentiment: Piper Sandler lowered its price target from $21 to $20 and assigned a “neutral” rating. The downgrade in target suggests analysts remain cautious about AMPH’s outlook and could temper the positive reaction to the quarterly beat. Piper Sandler price-target update

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.